Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Abbott Laboratories (ABTCL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
108,200.00 0.00    0.00%
05/04 - Delayed Data. Currency in CLP ( Disclaimer )
Type:  Equity
Market:  Chile
ISIN:  US0028241000 
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 105,680.00 - 105,680.00
Abbott Labs 108,200.00 0.00 0.00%

NYSE:ABTCL Financials

 
A brief overview of the NYSE:ABT financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Abbott over time.

Abbott Laboratories reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 10,241 million compared to USD 10,091 million a year ago. Net income was USD 1,594 million compared to USD 1,033 million a year ago. Diluted earnings per share from continuing operations was USD 0.91 compared to USD 0.59 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ABTCL Income Statement

Gross margin TTM 55.32%
Operating margin TTM 18%
Net Profit margin TTM 14.27%
Return on Investment TTM 11.47%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 10241 10143 9978 9747
Gross Profit 5710 5538 5495 5433
Operating Income 2057 1769 1663 1678
Net Income 1594 1436 1375 1318

ABTCL Balance Sheet

Quick Ratio MRQ 1
Current Ratio MRQ 1.64
LT Debt to Equity MRQ 35.23%
Total Debt to Equity MRQ 41.12%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 73214 72090 73354 73794
Total Liabilities 34387 34396 35950 36562
Total Equity 38827 37694 37404 37232

ABTCL Cash Flow Statement

Cash Flow/Share TTM 4.18
Revenue/Share TTM 23.1
Operating Cash Flow  21.95%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3038 1877 1203 1143
Cash From Investing Activities -824 -634 -1213 -462
Cash From Financing Activities -2052 -2340 -1289 -1410
Net Change in Cash 187 -1126 -1326 -721
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ABT Comments

Write your thoughts about Abbott Laboratories
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
James Cooley
James Cooley Mar 15, 2024 3:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what baby formula is all these companies being sued for?
Suraj Tschand
Suraj Tschand Mar 14, 2024 4:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ABT is a success story. There FreeStyle for diabetes is the best seller. The unit tells a diabetic person what foods cause the glucose spikes. The stock shot up because of their runaway successful Covid rapid tester. It has gone up by 20% this year and before we know it, it will be hitting $150.
Mauro Mariotti
Mauro Mariotti Sep 27, 2023 9:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Caspita sotto 100....
Michael Gad
Michael Gad Feb 10, 2023 9:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy 108.3
Jonah Garber
Jonah Garber Aug 08, 2022 1:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
wayne lim
wayne lim Aug 07, 2022 9:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
super boom
wayne lim
wayne lim Aug 07, 2022 9:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
super boom
sean delaney
sean delaney Sep 09, 2021 5:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Boom!!
John Cerniuk
John Cerniuk Jul 21, 2021 6:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
its coiled like a snake it's ready to spring
Mahdi Hatami
Mahdi Hatami Jun 15, 2021 10:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
best time to buy ABT!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email